Primera Analytical Solutions (Primera), an FDA-compliant analytical Contract Research Organization (CRO), has selected Cenevo’s Labguru electro...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (M...
Bio Usawa, a leader in expanding global access to biopharmaceuticals, and Nanoly Bioscience, a pioneer in chemical stabilization, announced a defin...
Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selecte...
Sapu Bioscience announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform, stre...
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced &nb...
QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 68838...
-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...
Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Ad...
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic...
Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. announced ...
FUJIFILM Biotechnologies expanded manufacturing and process development presence in the North East of England to support vital biomanufacturing innovativ...
EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies,announced the achiev...
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority co...
© 2026 Biopharma Boardroom. All Rights Reserved.
